Results 21 to 30 of about 1,716,154 (283)

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Journal of Medical Case Reports, 2022
Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory ...
Bai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Ju Bai, Yan Xu, Xu-Geng Wang, Rui-Li Zhang, Li-Li Wei, Qiu-Chuan Zhuang, Frank Fan, Wang-Gang Zhang, Ai-Li He, Jie Liu   +20 more
doaj   +1 more source

CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

JACC: Case Reports, 2023
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life ...
Choon Ta Ng, MBBS, Hilda M. Gonzalez Bonilla, MD, Ian Chang, MD, M. Tun Aung, MD, Jennifer J. Gile, MD, Naveen L. Pereira, MD, Jose C. Villasboas Bisneto, MD, Patrick B. Johnston, MD, Hector R. Villarraga, MD, Martin G. Rodriguez-Porcel, MD, Grace Lin, MD, Yi Lin, MD, PhD, Joerg Herrmann, MD   +12 more
doaj   +1 more source

Chimeric Antigen Receptor (CAR)-T Cell Therapy [PDF]

, 2018
Article信州医学雑誌 66(6): 425-433(2018)journal ...
齋藤, 章治, 中沢, 洋三
core   +1 more source

Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular Cloning

, 2022
Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular ...
Anthony J Bais (13285305)
core   +1 more source

Mesothelin-targeting chimeric antigen receptor–modified T cells by transposon system suppress the growth of bile duct carcinoma

Tumor Biology, 2017
Chimeric antigen receptor modified T cell–based immunotherapy is revolutionizing the field of cancer treatment. However, its potential in treating bile duct carcinoma has not been fully explored.
Jie-Ying Xu, Zhen-Long Ye, Du-Qing Jiang, Jiang-Chuan He, Yong-Mei Ding, Lin-Fang Li, Sai-Qun Lv, Ying Wang, Hua-Jun Jin, Qi-Jun Qian   +9 more
doaj   +1 more source

Unlocking the potential of Tregs: innovations in CAR technology

Frontiers in Molecular Biosciences, 2023
Regulatory T cells (Tregs) adoptive immunotherapy is emerging as a viable treatment option for both autoimmune and alloimmune diseases. However, numerous challenges remain, including limitations related to cell number, availability of target-specific ...
Christopher J. Requejo Cier, Nicolas Valentini, Caroline Lamarche   +2 more
doaj   +1 more source

Gene-modified T-cell Therapy Using Chimeric Antigen Receptor [PDF]

, 2013
Article信州医学雑誌 61(4):197-203(2013)journal ...
中沢, 洋三
core   +1 more source

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Haematologica, 2016
Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for antibody therapy.
Esther Drent, Richard W.J. Groen, Willy A. Noort, Maria Themeli, Jeroen J. Lammerts van Bueren, Paul W.H.I. Parren, Jürgen Kuball, Zsolt Sebestyen, Huipin Yuan, Joost de Bruijn, Niels W.C.J. van de Donk, Anton C.M. Martens, Henk M. Lokhorst, Tuna Mutis   +13 more
doaj   +1 more source

EXPRESSION OF A FUNCTIONAL CHIMERIC lg-MHC CLASS II PROTEIN [PDF]

, 1992
composed of the a- and ß-chains of the MHC class I1 I-E molecule fused to antibody V regions derived from anti-human CD4 mAb MT310. Expression vectors were constructed containing the functional, rearranged gene segments coding for the V region domains of
Zwirner, Jörg, Widera, Georg, Rieber, Ernst Peter, Karlsson, Lars, Peterson, Per A., Becker, Andrea, Weissenhorn, Winfried, Weiss, Elisabeth H., Riethmüller, Gert   +8 more
core   +1 more source

Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues ...
Alejandro Ramírez-Chacón, Alejandro Ramírez-Chacón, Sergi Betriu-Méndez, Sergi Betriu-Méndez, Ariadna Bartoló-Ibars, Ariadna Bartoló-Ibars, Azucena González, Azucena González, Azucena González, Mercè Martí, Mercè Martí, Manel Juan, Manel Juan, Manel Juan   +13 more
doaj   +1 more source